ISPCHealthcare · Diagnostics & ResearchTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 4 Nov 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores iSpecimen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ISPC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2022 | EF Hutton | Maintains | Buy | $5.50 → $4.25 |
| 4 Jan 2022 | Craig-Hallum | Initiates | Buy | — |
| 22 Nov 2021 | EF Hutton | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ISPC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, iSpecimen, Inc. returned −96.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 76% of US stocks
Cheaper than 27% of US stocks
Cheaper than 79% of US stocks
Cheaper than 61% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 56% of US stocks
Higher than 5% of US stocks
Higher than 50% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
iSpecimen, Inc. has a market value of $2.0M and an enterprise value of −$2.2M.
Revenue in the twelve months to 30 June 2026: $466K. The latest quarter shrank 78.7% year on year.
Net income over the same four quarters: −$11.4M, a −2449.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$8.7M, after $1.7M of capital spending.
Trailing P/E: −0.0×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
iSpecimen, Inc. employs 7 people — $67K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own iSpecimen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
iSpecimen announced expanded access to fully consented, prospectively collected healthy donor whole blood through an existing collection partner. The expanded capability offers researchers a streamlined sourcing option for blood collected specifically for research.
Why it matters — The announcement describes an expansion of iSpecimen’s access to research-focused biospecimens.
iSpecimen is supporting a hospital laboratory in validating a new chemistry analyzer for clinical use by identifying a healthcare system already using the same analyzer and coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid, and urine specimens for the validation process.
Why it matters — This highlights iSpecimen's role in a real clinical validation project and demonstrates demand for its biospecimen coordination services.
iSpecimen announced it completed a large-scale international cancer research order involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project required coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline.
Why it matters — The completion of a large international cancer research order on an accelerated timeline demonstrates iSpecimen's ability to source and fulfill substantial biospecimen projects.
iSpecimen Inc. announced the closing of its public offering of 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 shares of common stock, for aggregate proceeds of approximately $5.0 million. The company plans to use the proceeds for repayment of outstanding liabilities, potential acquisitions or investments, marketing and advertising services, and working capital.
Why it matters — The offering strengthens iSpecimen's cash position at a time when it is addressing liabilities and pursuing potential growth opportunities, which is relevant for shareholders monitoring the company's financial footing.
E.F. Hutton & Co. served as exclusive placement agent for iSpecimen's $5.0 million public offering. The engagement marks E.F. Hutton's third capital markets collaboration with iSpecimen since December 2025.
Why it matters — ISPC watchers would care because this shows continued capital-raising activity and ongoing investment-banking support for the company.
Of the 1 analysts covering iSpecimen, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iSpecimen, Inc. 23 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, iSpecimen, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No analyst covering iSpecimen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ISPC are extrapolating price history, which says nothing about the business.
iSpecimen, Inc. returned -96.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
iSpecimen Inc. is a technology-driven life sciences company that operates an online marketplace for human biospecimens and associated clinical data.
The most recent item we track (Newsfile Corp, 29 Oct 2026): "iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent". iSpecimen announced expanded access to fully consented, prospectively collected healthy donor whole blood through an existing collection partner. The expanded capability offers researchers a streamlined sourcing option for blood collected specifically for research.
iSpecimen Inc. is a technology-driven life sciences company that operates an online marketplace for human biospecimens and associated clinical data. The company connects researchers in industry, academia, and government with healthcare providers that supply biofluids, tissues, living cells, and other specimens needed for medical research. Its platform centralizes the sourcing, search, contracting, and compliance process, helping buyers access a broad network of providers through a single digital workflow. iSpecimen Inc. serves the biomedical research market by supporting studies in drug development, diagnostics, and translational medicine. Headquartered in Woburn, Massachusetts, iSpecimen Inc. focuses on improving the efficiency of biospecimen procurement and expanding access to research materials across global life science markets.
CEO Ms. Katharyn Field · 7 employees · United States · https://ispecimen.com
